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Aim: Providing a wide, tumor specific antigenic repertoire and standardized, sustained,
local delivery of potent adjuvant at the vaccination site is a major challenge in clinical
oncology. Combining the sc implantation of irradiated, autologous tumor cells and
biocompatible capsules containing GM-CSF secreting allogeneic cells recapitulates the
protective, tumor specific immunity obtained with irradiated tumor cells engineered to
produce gm-csf in murine models. Encapsulation cell technology (ECT) allows the stable,
local release of gm-csf without detrimental systemic effects. MVX-ONCO-1, combines
ECT for the sc delivery of huGM-CSF at the vaccination site, a key factor for successful
immunization and irradiated autologous tumor cells. MVX-ONCO-1 is the first in men
clinical trial assessing safety and feasibility of this innovative cell-based immunotherapy.
Methods: Primary Endpoints: Safety and Feasibility. Population: 15 patients, advanced
cancers progressing despite standard therapies. Treatment: Subcutaneous immunization
combining lethally irradiated autologous tumor cells(4x106) and 2 macrocapsules
containing cells genetically engineered to release stable quantity of GM-CSF over 7 days
(>20 ng/24 hours). 6 sc implantations are performed at week 1-2-3-4-6-8
Results: As of September 8, all 15 patients have been treated. Vaccination was
processed successfully for all patients. All cell therapy products met the GMP criteria.
Out of 172 capsules implantations, 1 presented with technical issue after removal.
Stable level of GM-CSF was observed in all explanted capsules tested. No treatment
related SAE or systemic AE have been reported. No SUSAR were observed. Toxicity is
limited to local discomfort. 7 out of 13 evaluable pts had some clinical benefit (SD > 3
months, decrease serum tumor marker, prolonged survival).
Conclusions:MVX-ONCO-1 is the first personalized anti-tumor immunotherapy
based on ECT. It is both safe and reliable. This innovative therapy is applicable to any
tumor type. Phase 2 trials are planned in several tumor types as well as combination
with immune check-point inhibitors.
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